We are live on
!
Find out more
Deep Track Capital Portfolio holdings
AUM
$6.87B
Turnover
41.46%
1-Year Est. Return
205.24%
This Fund
S&P 500
This Quarter
Est. Return
+8.81%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.12B
AUM Growth
+$515M
(+9.2%)
Cap. Flow
+$659M
Cap. Flow
% of AUM
10.76%
Top 10 Holdings %
Top 10 Hldgs %
53.58%
Holding
69
New
14
Increased
25
Reduced
14
Closed
6
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alumis Inc
ALMS
|
+$169M |
| 2 |
Nuvalent
NUVL
|
+$140M |
| 3 |
Ocular Therapeutix
OCUL
|
+$111M |
| 4 |
Genmab
GMAB
|
+$110M |
| 5 |
Vera Therapeutics
VERA
|
+$55.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dynavax Technologies
DVAX
|
+$242M |
| 2 |
Cytokinetics
CYTK
|
+$125M |
| 3 |
Apellis Pharmaceuticals
APLS
|
+$69.3M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$67.1M |
| 5 |
Maze Therapeutics
MAZE
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.14% |
| 2 | Miscellaneous | 20.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.91B
| $1.28B | 20.86% |
10,000,000
| – | – |
2025 Q4
1 quarter
|
|
2
Guardant Health
GH
$22.3B
| $308M | 5.04% |
3,338,241
+538,241
| +19% | +$54M |
2023 Q2
11 quarters
|
|
3
Immunovant
IMVT
$5.68B
| $286M | 4.68% |
11,526,971
| – | – |
2021 Q4
17 quarters
|
|
4
Tarsus Pharmaceuticals
TARS
$3.33B
| $253M | 4.12% |
3,600,000
+595,966
| +20% | +$41.6M |
2025 Q1
4 quarters
|
|
5
Vaxcyte
PCVX
$10.3B
| $250M | 4.08% |
4,300,000
+300,000
| +8% | +$16.3M |
2025 Q1
4 quarters
|
|
6
Structure Therapeutics
GPCR
$1.58B
| $206M | 3.37% |
4,279,848
+168,066
| +4% | +$11.5M |
2023 Q1
12 quarters
|
|
7
Axsome Therapeutics
AXSM
$8.49B
| $186M | 3.04% |
1,100,000
-50,000
| -4% | -$8.64M |
2025 Q2
3 quarters
|
|
|
8
DELISTED
Apellis Pharmaceuticals
APLS
| $182M | 2.98% |
4,532,374
-3,217,626
| -42% | -$69.3M |
2024 Q1
8 quarters
|
|
|
9
Ocular Therapeutix
OCUL
$1.62B
| $167M | 2.72% |
19,686,282
+11,615,868
| +144% | +$111M |
2023 Q4
9 quarters
|
|
|
10
Vera Therapeutics
VERA
$2.06B
| $165M | 2.7% |
4,106,067
+1,284,932
| +46% | +$55.4M |
2025 Q4
1 quarter
|
|
|
11
Alumis Inc
ALMS
$819M
| $149M | 2.44% |
+6,772,595
| New | +$169M |
2026 Q1
0 quarters
|
|
12
Ionis Pharmaceuticals
IONS
$7.32B
| $146M | 2.39% |
1,950,000
+250,000
| +15% | +$19.7M |
2022 Q4
13 quarters
|
|
|
13
DELISTED
Nuvalent
NUVL
| $141M | 2.3% |
+1,376,324
| New | +$140M |
2026 Q1
0 quarters
|
|
14
Alkermes
ALKS
$6.72B
| $127M | 2.07% |
3,590,323
+1,590,323
| +80% | +$49.3M |
2025 Q4
1 quarter
|
|
|
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
| $125M | 2.05% |
3,158,041
+1,158,041
| +58% | +$29.6M |
2025 Q4
1 quarter
|
|
16
MoonLake Immunotherapeutics
MLTX
$874M
| $119M | 1.95% |
6,408,863
+1,798,792
| +39% | +$29.8M |
2025 Q4
1 quarter
|
|
|
17
Maze Therapeutics
MAZE
$1.52B
| $104M | 1.7% |
3,477,562
-768,878
| -18% | -$33.9M |
2025 Q1
4 quarters
|
|
18
Oruka Therapeutics
ORKA
$4.89B
| $99.8M | 1.63% |
2,034,203
-127,307
| -6% | -$4.42M |
2024 Q3
6 quarters
|
|
19
Nurix Therapeutics
NRIX
$2.72B
| $98.4M | 1.61% |
6,345,244
-691,211
| -10% | -$11.5M |
2022 Q2
15 quarters
|
|
|
20
Genmab
GMAB
$23.3B
| $98.3M | 1.61% |
+3,663,250
| New | +$110M |
2026 Q1
0 quarters
|
|
|
21
Cytokinetics
CYTK
$8.89B
| $90.6M | 1.48% |
1,374,320
-1,962,678
| -59% | -$125M |
2024 Q2
7 quarters
|
|
22
GRAIL Inc
GRAL
$6.05B
| $89M | 1.45% |
1,722,797
+700,000
| +68% | +$54.2M |
2025 Q4
1 quarter
|
|
23
LB Pharmaceuticals
LBRX
$1.19B
| $82.7M | 1.35% |
3,352,804
| – | – |
2025 Q3
2 quarters
|
|
24
MBX Biosciences
MBX
$2.44B
| $82.3M | 1.34% |
2,757,569
-492,221
| -15% | -$16.7M |
2024 Q3
6 quarters
|
|
25
Bicara Therapeutics
BCAX
$1.16B
| $80.8M | 1.32% |
4,062,500
+1,448,496
| +55% | +$24.9M |
2024 Q3
6 quarters
|
|
Similar funds
Deep Track Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Deep Track Capital held 69 positions worth $6.12B, up 9.2% from $5.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Deep Track Capital deployed $659M of net new capital in Q1 2026, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was Alumis Inc: 6,772,595 shares worth $149M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Cytokinetics, an estimated $125M trimmed.
- Deep Track Capital's largest Q1 2026 buy was Alumis Inc: 6,772,595 shares worth $149M.
- Deep Track Capital added most to Ocular Therapeutix in Q1 2026, an estimated $111M increase.
- Deep Track Capital's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $125M.
- Deep Track Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $242M.
- Deep Track Capital's ten largest holdings make up 54% of its $6.12B portfolio in Q1 2026.
- Deep Track Capital opened 14 new positions and closed 6 in Q1 2026.
- Deep Track Capital's portfolio value rose 9.2% quarter-over-quarter to $6.12B.
Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.